4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $29.8750.

Several equities research analysts recently issued reports on FDMT shares. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Chardan Capital restated a “buy” rating and set a $26.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. Jefferies Financial Group reaffirmed a “buy” rating and set a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. Finally, Royal Bank Of Canada boosted their price target on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday, March 19th.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Wexford Capital LP acquired a new stake in shares of 4D Molecular Therapeutics during the third quarter worth approximately $41,000. Daiwa Securities Group Inc. boosted its stake in 4D Molecular Therapeutics by 3,362.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after acquiring an additional 6,186 shares during the last quarter. Abich Financial Wealth Management LLC acquired a new position in 4D Molecular Therapeutics during the 3rd quarter worth $80,000. Susquehanna Portfolio Strategies LLC acquired a new position in 4D Molecular Therapeutics during the 4th quarter worth $77,000. Finally, Martingale Asset Management L P increased its position in shares of 4D Molecular Therapeutics by 12.4% in the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock worth $88,000 after purchasing an additional 1,303 shares during the last quarter. 99.27% of the stock is owned by institutional investors and hedge funds.

4D Molecular Therapeutics Stock Up 6.8%

FDMT opened at $9.23 on Wednesday. The firm has a market capitalization of $482.54 million, a P/E ratio of -3.59 and a beta of 2.75. The firm’s 50 day moving average is $9.50 and its 200-day moving average is $9.22. 4D Molecular Therapeutics has a 52-week low of $3.68 and a 52-week high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The firm had revenue of $3.05 million for the quarter, compared to analyst estimates of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. Equities analysts expect that 4D Molecular Therapeutics will post -3.8 earnings per share for the current fiscal year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.